Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Ophir agrees to be bought by Indonesia's Medco in a sweetened bid

Published 21/03/2019, 02:37
Updated 21/03/2019, 02:37
© Reuters.  Ophir agrees to be bought by Indonesia's Medco in a sweetened bid

By Shubham Kalia

(Reuters) - London-listed Ophir Energy Plc (LON:OPHR) said on Wednesday it agreed to be bought by Indonesian oil and gas group Medco for a sweetened cash bid of 408.4 million pounds after previously agreeing to a lower offer.

Under the terms, Ophir shareholders will receive 57.5 pence per share in cash, the companies said in a joint statement. That is up from the previously agreed 55 pence per share.

The increased offer comes after the Financial Times reported that hedge fund Petrus Advisers, which owns 3.94 percent of Ophir, planned to vote against Medco's bid because it undervalued the company.

Petrus in February had called for alternatives to Medco's buyout offer and asked the company to put Petrus-backed directors in charge of overseeing the proposed changes.

Ophir, which explores and produces oil and gas in Asia and Africa, and Medco were not immediately available to comment on the Financial Times report.

Ophir also received an offer earlier this month from Coro Energy plc, according to which Ophir shareholders would receive 40 pence in cash, and in addition, shares in Coro for each Ophir Share, resulting in an ownership by Ophir shareholders of between 85 per cent. and 95 percent of the enlarged company.

Ophir said on Wednesday that Coro does not intend to proceed with its proposal after the deal between Ophir and Medco.

Medco said its offer of 57.5 pence per share is final and would not be increased. Ophir's directors recommended that the shareholders vote in favour of the deal, it said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

A meeting in connection with the increased offer will be held on March 25, Ophir added.

The offer price is at a premium of about 73 percent to Ophir's closing price on Dec. 28, the last trading day before Medco first announced a possible offer and a premium of about 2.7 percent to Ophir's Wednesday close of 56 pence.

Medco plans to fund the deal by proceeds of a credit agreement and from its existing cash resources.

The Jakarta-headquartered company had previously said that the deal would be immediately accretive in the first full year to its EBITDA and net income.

Ophir in January rejected a $437 million, or 48.5 pence per share offer from Medco, saying it undervalued the company.

Standard Chartered (LON:STAN) Bank acted as financial adviser to Medco while Morgan Stanley (NYSE:MS) and Lambert Energy Advisory advised Ophir.

Founded by oil and gas tycoon Arifin Panigoro, Medco has made sizeable acquisitions in recent years, including leading a $2.6 billion acquisition of the Indonesian unit of Newmont Mining Corp (NYSE:NEM) in November 2016.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.